About
Studies have indicated that oestrogen levels can affect joint laxity, particularly in women during pregnancy and post-menopause, where oestrogen levels decline sharply. The role of hormones in exacerbating hypermobility syndromes, during these phases is often under-recognized. Fluctuations in progestogen and oestrogen levels play a part in all of these phases.
The Patient Global Impression of Change scores indicated a significantly positive impact of testosterone on participant’s perception of improvement in his walking ability overall and separately in men enrolled and not enrolled in the PFT. Thus, testosterone should probably not be started specifically to improve physical function, but men who are treated with testosterone for other reasons may experience some improvement in physical function. The overall treatment effect on 6MWD was small, but not dissimilar from that of a physical activity intervention in older adults with mobility limitation (29). Additionally, we included a patient global impression of change to corroborate whether the patients perceived their walking speed to have improved. We asked men at each visit whether they perceived any changes in their walking ability since the start of the trial using a 7-point scale ranging from "much worse" to "much better" (PGIC).
The effect of testosterone on mobility measures were related to baseline gait speed and self-reported mobility limitation, and changes in testosterone and haemoglobin concentrations. Unlike many previous trials, which enrolled healthy older men without functional limitations, PFT enrolled men who not only had self-reported mobility limitation, but also had slow gait speed assessed objectively using the 6-minute walk test. While there is a consensus that testosterone replacement of androgen-deficient men increases fat-free mass, its effects on muscle performance and physical function have been inconsistent across trials.
AbbVie (formerly Solvay and Abbott Laboratories) generously provided funding and donated AndroGel and placebo gel. These findings of the PFT are important in the context of the substantial pharmaceutical investment in exploring the application of androgens as function promoting therapies. In 2002 the National Institute on Aging (NIA) requested that the Institute of Medicine (IOM) assess the status of clinical research on testosterone therapy in older men. The number of men reporting falls or seeking medical attention for fall-related injuries during the year on treatment was similar in each treatment group. We assumed the minimal clinically important difference in 6MWD to be 50 meters, based on the information from epidemiologic studies available at the time the trial was designed (25–27). The time X treatment interaction was not statistically significant; thus the apparent fluctuations in PF10 scores over time may be a chance finding.
Sign up for muscle-building workouts, expert weight loss advice, and nutritious meal plans, delivered to your email daily. It’s important to consult with a healthcare professional to determine if TRT is suitable for you and to manage any potential risks or side effects. By promoting the production of synovial fluid and maintaining bone density, TRT can alleviate joint discomfort and enhance mobility. Testosterone plays a significant role in joint health and mobility for men. Adhering to the prescribed treatment plan and maintaining a healthy lifestyle, including regular exercise and a balanced diet, can help optimize the benefits of TRT for joint health.
This is because the lack of testosterone can result in the thinning of cartilage, the protective tissue that covers the ends of bones in a joint. Testosterone plays a crucial role in maintaining joint health and mobility. One area that can be significantly impacted is joint health and mobility. The authors thank Dr. Wildon Farwell and colleagues at the VA Boston Healthcare System for their efforts to establish the VA investigational site for this study. Collectively, these steps reflect a committed effort to ensuring the health and safety of study participants. There is significant controversy with respect to the safety of testosterone administration in older individuals. We acknowledge that age-related limitations in mobility are complex and multifactorial.
The change in PF10 from baseline in men treated with testosterone was not significantly related to the change in total and free testosterone, DHT and estradiol level (data not shown). Serum free testosterone, DHT and estradiol concentrations also increased in the testosterone group, but did not change in the placebo group. The men enrolled in the PFT were on average older, had higher BMI, were more likely to have comorbid conditions, and, as expected, had slower gait speed and lower PF10 score than those not enrolled in this trial. The two intervention groups were similar in their baseline characteristics among men enrolled and not enrolled in the PFT (Table 1), among men whose baseline gait speed was Supplementary tables 1 and 2). Among the 390 men who were enrolled in the PFT, 35 withdrew prior to month 12, 13 in the testosterone group and 22 in the placebo group (CONSORT diagram; Figure 1). As described (19), among 790 men who were enrolled in the TTrials, 390 were enrolled in the PFT; 193 men were allocated to the testosterone arm and 197 to the placebo arm.
Therefore, it would be expected to improve those measures of physical function and mobility which are dependent upon lower extremity strength. It is possible that in the participants enrolled in this trial, the MCID for 6MWD may be lower than this estimate, as suggested by the fact that a greater proportion of men in the testosterone arm perceived their walking ability to have improved even though the mean change in 6MWD was substantially smaller than 50 meters. As the anabolic effects of testosterone on the skeletal muscle are related to increase in testosterone concentrations (12), we also evaluated the relation of changes in hormone levels with the changes in 6MWD and PF-10 in all men participating in the TTrials. Secondary outcomes included change in 6MWD as a continuous variable, change in 6MWD in all men enrolled in the TTrials, and self-reported physical function, assessed using the physical function component (PF10) of the Medical Outcomes Study Short Form-36 (MOS SF36) (28). By ensuring adequate levels of testosterone, TRT promotes the growth and strength of bones, reducing the risk of fractures and improving joint function. Research has shown that low testosterone levels can lead to joint pain, stiffness, and decreased mobility. As men age, they may experience a decline in testosterone levels, which can have various effects on their overall health.
The study intervention is a daily application of a transdermal gel containing either placebo or 100 mg testosterone (Testim 1%, Auxilium Pharmaceuticals, Norristown, PA) for 6 months (24 weeks). The gradual but progressive decrease in serum testosterone from age 20 to 80 14–16 and indisputable evidence that testosterone supplementation increases skeletal muscle mass not only in states of health 17, 18, but also disease 19–22 and older age 23–26, have underscored its potential as a function promoting anabolic therapy. The causality of limitations in physical function and mobility is without doubt complex and multifactorial. The socioeconomic costs of these sequelae and the aging epidemic have exposed an unmet need for therapies to improve physical function and mobility in older individuals. Limitations in physical function and mobility consequent to advancing age represent a far-reaching public health burden in the United States; a society in which 20% of the population will be 65 years of age or older in 2030. The primary objective is to determine whether testosterone therapy improves maximal voluntary muscle strength as quantified by the one repetition maximum.
Gender: Female
